The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives

MLA

Rehana Z Hussain, et al. “The Sequential Natalizumab – Alemtuzumab Therapy in Patients with Relapsing Forms of Multiple Sclerosis (SUPPRESS) Trial – Part I: Rationale and Objectives.” Journal of Central Nervous System Disease, vol. 14, Aug. 2022. EBSCOhost, https://doi.org/10.1177/11795735221123911.

APA

Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, & Olaf Stuve. (2022). The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives. Journal of Central Nervous System Disease, 14. https://doi.org/10.1177/11795735221123911

Chicago

Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, and Olaf Stuve. 2022. “The Sequential Natalizumab – Alemtuzumab Therapy in Patients with Relapsing Forms of Multiple Sclerosis (SUPPRESS) Trial – Part I: Rationale and Objectives.” Journal of Central Nervous System Disease 14 (August). doi:10.1177/11795735221123911.